NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 251)
Posted On: 07/01/2019 4:02:51 PM
NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Provides Update on Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer
Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning provided an update on the development of its lead drug candidate, Oncoprex(TM) immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (“NSCLC”). Based on data from the ongoing study through GNPX’s July 2018 sponsored research agreement with The University of Texas MD Anderson Cancer Center, as well as prior clinical and pre-clinical studies, Genprex is working with its scientific advisory board and outside consultants to design a clinical trial for Oncoprex. According to the update, the new study will focus on Oncoprex in combination with a checkpoint inhibitor for the treatment of NSCLC, with a goal of enrolling patients in the first quarter of 2020. “Recent studies have shown that less than half of cancer patients qualify for approved immunotherapies based on the patient’s PD-1 or PD-L1 protein expression level,” Genprex President and COO Julien Pham said in the news release. “Current immunotherapy treatment is only benefitting a small number of cancer patients. We are working to fill this gap by combining our lead drug candidate with approved immunotherapies to give patients more treatment options. The preclinical studies have shown encouraging data that this combination could be a viable treatment option for late-stage non-small cell lung cancer.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning provided an update on the development of its lead drug candidate, Oncoprex(TM) immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (“NSCLC”). Based on data from the ongoing study through GNPX’s July 2018 sponsored research agreement with The University of Texas MD Anderson Cancer Center, as well as prior clinical and pre-clinical studies, Genprex is working with its scientific advisory board and outside consultants to design a clinical trial for Oncoprex. According to the update, the new study will focus on Oncoprex in combination with a checkpoint inhibitor for the treatment of NSCLC, with a goal of enrolling patients in the first quarter of 2020. “Recent studies have shown that less than half of cancer patients qualify for approved immunotherapies based on the patient’s PD-1 or PD-L1 protein expression level,” Genprex President and COO Julien Pham said in the news release. “Current immunotherapy treatment is only benefitting a small number of cancer patients. We are working to fill this gap by combining our lead drug candidate with approved immunotherapies to give patients more treatment options. The preclinical studies have shown encouraging data that this combination could be a viable treatment option for late-stage non-small cell lung cancer.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)